Teva could help with Covid Vaccine Rollout
Recent reports – Teva Pharmaceutical Industries Ltd. may get involved in Vaccine rollout to help speed up the process of Covid-19 Vaccine Rollout according to Bloomberg News and other sources.
Teva Pharmaceutical Industries Ltd. is in talks with Covid-19 vaccine makers about helping to produce and distribute shots as demand rises for immunizations.
The generic drug giant is offering to dedicate its manufacturing capacity in the U.S., Europe and beyond to aid with mass-immunization efforts geared at combating the pandemic, Chief Executive Officer Kare Schultz said Wednesday.
“We have a large, worldwide network of manufacturing capabilities,” from creating underlying drug substances to putting solutions into sterile vials, known as the fill-finish process, he said in an interview. “There are a limited number of facilities that can do this kind of manufacturing, and it takes time to build them.”
Searchitlocal Editor
I think any company that steps up and helps move the rollout of vaccines for Covid-19 should enter the process to assist. When you’re talking about Vaccinating an entire world all parties can step up and help. Don’t you agree?
A few days ago CEO Kare Schultz was seen on “Squawk on the Street” to discuss the rollout and the rollout in Iseral which is also where the corporate offices are for Teva Pharmaceutical is located.
Covid-19 requires mass-immunization and given Teva, is known to be one of the largest generic drug makers in the world it only seems logical that they would join in to assist.
Who is Teva?
You may wonder who Teva is, and where they came from so In 1964, Assia and Zori merged and in 1968 acquired a controlling stake in Teva. In 1976, the three companies merged into the modern-day Teva Pharmaceutical Industries Ltd. They say that nearly 200 million people in over 50 countries benefit from the drugs Teva produces. Teva is the leading generic medicine company in North America, where 1 of every 9 prescriptions in the US and 1 of every 6 generic prescriptions in Canada are produced by this behemoth of a drug maker.
In the last few years, this drugmaker has come under attack with heavy debt to help avoid a takeover and develop new drugs, as well as being a target of several states in the United States for being part of the opioid crisis. The stock that once was in the $30 dollar range fell and rose a number of times over the last few years. Its current target is suggested by some analysts are from as low as $9 to a high of $20.
